PRMT5 INHIBITORS AND USES THEREOF
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.
1 .- 88 . (canceled)
89 . A pharmaceutical composition comprising a compound selected from the following:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
90 . A kit or packaged pharmaceutical comprising a compound selected from the following:
or a pharmaceutically acceptable salt thereof, and instructions for use thereof.
91 . A method of inhibiting PRMT5 comprising contacting a cell with an effective amount of a compound selected from the following:
or a pharmaceutically acceptable salt thereof.
92 . A method of altering gene expression comprising contacting a cell with an effective amount of a compound selected from the following:
or a pharmaceutically acceptable salt thereof.
93 . A method of altering transcription comprising contacting a cell with an effective amount of a compound selected from the following:
or a pharmaceutically acceptable salt thereof.
94 . The method of claim 91 , wherein the cell is in vitro.
95 . The method of claim 91 , wherein the cell is in a subject.
96 . A method of treating a PRMT5-mediated disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the following:
or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 89 .
97 . The method of claim 96 , wherein the disorder is a proliferative disorder.
98 . The method of claim 97 , wherein the disorder is cancer.
99 . The method of claim 98 , wherein the cancer is hematopoietic cancer, lung cancer, prostate cancer, melanoma, or pancreatic cancer.
100 . The method of claim 96 , wherein the disorder is a metabolic disorder.
101 . The method of claim 100 , wherein the metabolic disorder is diabetes.
102 . The method of claim 100 , wherein the metabolic disorder is obesity.
103 . The method of claim 96 , wherein the disorder is a blood disorder.
104 . The method of claim 103 , wherein the disorder is a hemoglobinopathy.
105 . The method of claim 104 , wherein the disorder is sickle cell anemia.
106 . The method of claim 104 , wherein the disorder is β-thalessemia.